Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
The aim of the study is to determine if Iressa added to radiotherapy is effective and safe in shrinking tumour dimensions.
Head and Neck Cancer|Carcinoma, Squamous Cell
DRUG: Iressa (Gefitinib)|PROCEDURE: Radiotherapy
Tumour Response Rate, as complete response (CR) and partial response (PR) . Six months after Last Patient In.
Time to progression, Overall survival, Duration of response. Six months after Last Patient In.
The aim of the study is to determine if Iressa added to radiotherapy is effective and safe in shrinking tumour dimensions.